
-
Victims of London 7/7 attacks remembered as king hails 'spirit of unity'
-
Poland starts border checks with Germany in anti-migrant clampdown
-
Wiaan Mulder: slow ascent to Test cricket's batting heights
-
England coach McCullum says paceman Archer 'ready to go' against India
-
Djokovic, Sinner on Wimbledon collision course
-
Vaughan says Crawley 'lucky' to have so many England caps
-
Russian forces claim first foothold in new Ukraine region
-
US envoy says satisfied with Lebanese response on disarming of Hezbollah
-
European stocks, dollar firm as US tariff deadline looms
-
Wimbledon blames 'human error' for embarrassing line-calling glitch
-
Three things learned from British Grand Prix
-
NGOs laud tougher Malaysia plastic trash import laws
-
Mulder makes highest South Africa Test score
-
UK marks London 7/7 attacks as king hails 'spirit of unity'
-
Apple appeals 500-mn-euro EU fine
-
Crowds celebrate Nepal ex-king's birthday in show of support
-
Bali flights nixed after huge Indonesia volcano eruption
-
Hamas, Israel resume talks as Netanyahu set to meet Trump
-
Hong Kong fans queue for opening of Cristiano Ronaldo exhibition
-
Itoje back as Lions take no chances against ACT Brumbies
-
Stock markets struggle as Trump's tariff deadline looms
-
Nearly 450,000 Afghans left Iran since June 1: IOM
-
North Korea bars Western influencers from trade fair tour
-
Typhoon Danas kills two, injures hundreds in Taiwan
-
Dutch coastal village turns to tech to find lost fishermen
-
Boxer Chavez's appeal against arrest if deported from US rejected: Mexico prosecutor
-
India captain Gill hailed back home after 'brilliant' Test win
-
The making of Australia's mushroom murders
-
Indonesia volcano spews 18-kilometre ash tower
-
Youthful Chelsea ready for Thiago Silva reunion at Club World Cup
-
Australian inquiry cites racism in Indigenous shooting
-
Djokovic wary despite Wimbledon form, dominant Sinner faces Dimitrov
-
Australian woman found guilty of triple murder with toxic mushrooms
-
Indonesia volcano spews 18-kilometre ash tower: agency
-
Trump says to send first tariff letters on Monday
-
The strange case of Evgeniya Mayboroda, Russia's rebel retiree
-
Asian markets drop as Trump's tariff deadline looms
-
Under-strength Brumbies eye 'big opportunity' against Lions
-
Macron to rekindle relationship with Francophile King Charles on UK visit
-
Trump hosts Netanyahu, hopes for Israel-Hamas deal 'this week'
-
Pressed to confess: Japan accused of 'hostage justice'
-
Demna to bow out at Balenciaga in Paris Haute Couture Week
-
Host of internationals in Australia-New Zealand squad to face Lions
-
Egyptian conservators give King Tut's treasures new glow
-
Mexico defeat USA 2-1 to retain CONCACAF Gold Cup
-
Visa's 24/7 war room takes on global cybercriminals
-
BRICS nations slam Trump tariffs, condemn strikes on Iran
-
Ondas Holdings Enters Strategic Partnership with KLEAR to Expand Access to Non-Dilutive Working Capital Across the Emerging Defense Technology Ecosystem
-
Innodata to Report Second Quarter 2025 Results
-
Sekur Private Data Ltd. Appoints Christophe Kabeya as Government and Corporate Sales Director for Central and Southern Africa

US panel recommends Covid vaccines for youngest children
A panel of experts convened by the US Food and Drug Administration unanimously recommended Covid-19 vaccines Wednesday for children under five, the final age group awaiting immunization in most countries.
Formal authorizations should follow soon, with the first shots in arms expected early next week, just over a year-and-a-half after the first Covid vaccines were greenlighted for the elderly in December 2020.
"This recommendation does fill a significant unmet need for a really ignored younger population," said Michael Nelson, a professor of medicine at the University of Virginia, one of the 21 experts asked to vote for the milestone meeting.
Unlike regulators in other countries, FDA offers livestreams of its internal deliberations and its stamp of approval is considered the global gold standard.
Opening the discussion, senior FDA scientist Peter Marks said that despite studies showing the majority of children have now been infected with the coronavirus, the high rate of hospitalizations among infants, toddlers and young children during last winter's Omicron wave underscored an urgent need for vaccination.
"We are dealing with an issue where we have to be careful we don't become numb to the pediatric deaths because of the overwhelming number of older deaths," he said.
"Every life is important and vaccine-preventable deaths are something we would like to try to do something about."
The United States has recorded 480 Covid deaths in the 0-4 age group in the pandemic -- far higher than even a bad flu season, Marks said.
As of May 2022, there have been 45,000 hospitalizations in that group, nearly a quarter of which required intensive care.
Ahead of the meeting, the FDA posted its independent analyses of the pharmaceutical companies' vaccines, deeming both safe and effective.
Both vaccines are based on messenger RNA, which delivers genetic code for the coronavirus spike protein to human cells that then grow it on their surface, training the immune system to be ready. The technology is now considered the leading Covid vaccination platform.
Pfizer sought authorization for three doses at three micrograms given to children aged six months through four years, while Moderna asked for the FDA to authorize its vaccine as two doses of a higher 25 micrograms for ages six months through five years.
Both vaccines were tested in trials of thousands of children. They were found to cause similar levels of mild side effects as in older age groups and triggered similar levels of antibodies.
- Two doses, or three? -
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent, compared to Moderna's estimates of 51 percent for children aged six-months to two years old and 37 percent for those aged two to five years.
But the Pfizer figure is based on very few cases and is thus considered preliminary. It also takes three doses to achieve its protection, with the third shot given eight weeks after the second, which is given three weeks after the first.
Moderna's vaccine should provide strong protection against severe disease after two doses, given four weeks apart, and the company is studying adding a booster that would raise efficacy levels against mild disease.
However, Moderna's decision to go with a higher dose is associated with higher levels of fevers in reaction to the vaccine compared to Pfizer.
There are some 20 million US children aged four years and under.
Although obesity, neurological disorders and asthma are associated with increased risk of severe disease among young children, it's not easy to predict severe outcomes.
In fact, 64 percent of hospitalizations in those under five occurred in patients without comorbidities.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition. Some three to six percent can experience long Covid symptoms for more than 12 weeks.
The FDA is expected to soon act on the panel's recommendation, and the matter will go to the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of 10 million shots at pharmacies and doctors' offices could begin as soon as June 21.
J.Williams--AMWN